First indigenously designed and manufactured artificial aortic valve for patients who are at a high risk of undergoing open heart valve replacement surgery was launched by the global medical device maker Meril Life Sciences. The launch is a significant breakthrough of Make in India initiative.
The Transcatheter Aortic Heart Valve Replacement (TAVR), which will be sold under the brand name "Myval", is a minimally invasive procedure in which the doctor places a artificial valve into the patient's diseased valve via a catheter inserted through the femoral artery (large artery in groin).
Prosthetic Heart Valves
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a heart valve that has become damaged.
Advertisement
‘TAVR is a less invasive method with fast recovery and is preferred as an alternative to surgical valve replacement.’
Tweet it Now
It is an alternative way to replace diseased valves without undergoing traditional open heart procedure, which some patients may not receive well.
"Meril is the first Indian company to commercially make this therapy available in the country. Through the commercialization of this technology, Meril will soon bring the next generation treatment modality to thousands of patients across the country and globally," said Sanjeev Bhatt, VP Corporate Strategy, Meril Life Sciences.
![Aortic Valve Stenosis]( "Aortic Valve Stenosis")
Aortic valve Stenosis is an abnormal narrowing of the c valve. Symptoms include angina, and that of heart failure. Aortic valve replacement is effective therapy.
TAVR has been dominated by US-based medical devices makers Medtronics and Edwards Lifesciences.
"The novel Myval technology is associated with zero new pacemaker implantation rates post procedure (which is an important benefit for the patient already treated for valve replacement). Pacemaker is an additional device that may be placed post TAVR procedure," Bhatt told IANS.
"Keeping healthcare for all in mind, the price of the technology will be well within the range," he added.
The company has also received an approval from the Indian drug regulator Central Drugs Standard Control Organisation (CDSCO) for commercialization of TAVR.
The approval is based on successful results from a clinical trial done in India, involving 14 hospitals -- Fortis and Medanta-The Medicity and Eternal Hospital, Jaipur, to name a few, Bhatt said.
"The development of this valve, which is implanted non-surgically through a catheter is a great achievement for the 'Made in India' initiative that such an important R&D has happened from India in a field which till now has been dominated by only American devices," Principal Investigator Ashok Seth, Chairman of Fortis Escorts Heart Institute, told IANS.
TAVR is increasingly becoming a preferred alternative for surgical valve replacement because it is associated with faster recovery time.
"The first patient to receive Myval has completed 1.5 years and is living a symptom-free productive life. The valve was effective in relieving the patient's symptoms and reducing the death and hospitalization from the aortic stenosis," according to Ravinder Singh Rao, Interventional Cardiologist at Eternal.
"Myval TAVR technology will be a boon for millions of patients suffering from aortic stenosis," Rao said.
No major adverse cardiac, cerebral and renal events were observed at six-months follow-up and zero mortality among the patients in the trial.
Source: IANS
Aortic Valve Stenosis
Aortic valve Stenosis is an abnormal narrowing of the c valve. Symptoms include angina, and that of heart failure. Aortic valve replacement is effective therapy.
Advertisement
TAVR has been dominated by US-based medical devices makers Medtronics and Edwards Lifesciences.
"The novel Myval technology is associated with zero new pacemaker implantation rates post procedure (which is an important benefit for the patient already treated for valve replacement). Pacemaker is an additional device that may be placed post TAVR procedure," Bhatt told IANS.
"Keeping healthcare for all in mind, the price of the technology will be well within the range," he added.
The company has also received an approval from the Indian drug regulator Central Drugs Standard Control Organisation (CDSCO) for commercialization of TAVR.
The approval is based on successful results from a clinical trial done in India, involving 14 hospitals -- Fortis and Medanta-The Medicity and Eternal Hospital, Jaipur, to name a few, Bhatt said.
"The development of this valve, which is implanted non-surgically through a catheter is a great achievement for the 'Made in India' initiative that such an important R&D has happened from India in a field which till now has been dominated by only American devices," Principal Investigator Ashok Seth, Chairman of Fortis Escorts Heart Institute, told IANS.
TAVR is increasingly becoming a preferred alternative for surgical valve replacement because it is associated with faster recovery time.
"The first patient to receive Myval has completed 1.5 years and is living a symptom-free productive life. The valve was effective in relieving the patient's symptoms and reducing the death and hospitalization from the aortic stenosis," according to Ravinder Singh Rao, Interventional Cardiologist at Eternal.
"Myval TAVR technology will be a boon for millions of patients suffering from aortic stenosis," Rao said.
No major adverse cardiac, cerebral and renal events were observed at six-months follow-up and zero mortality among the patients in the trial.
Source: IANS
Mitral Valve Regurgitation and Mitral Valve Replacement
Mitral valve replacement is replacing the diseased mitral valve with an artificial valve.
Advertisement
 Mitral Valve Stenosis And Mitral Valve ReplacementMitral valve replacement is a surgical heart procedure to correct either the narrowing (stenosis) or the leakage (regurgitation). | Advertisement
|
Advertisement
Recommended Readings
Latest Indian Health News
The Rs 1,500 crore 'Chief Minister Health at Doorstep' program aims to cut expenses and conduct blood tests for those aged 60+.
In Bihar, a mysterious ailment named "Langda fever" by locals has emerged, causing patients to recover from fever but struggle to walk due to joint pain.
Upon analyzing the years of life lost due to cancer, the team discovered that the four avoidable risk factors led to an annual loss of over 30 million years of life.
Over the past three to four weeks in Delhi, there has been an increase of 20-30% in patients with recurring cough and upper respiratory tract infections.
Premature infants with gastrointestinal complications and metabolic disorders stand to benefit the most from this Lactarium initiative.